The completion of the acquisition of two major multinational pharmaceutical companies is related to Novartis and Boehringer Ingelheim

Article source: Medical Rubik's Cube Info

Author: Sunshine

On September 21, Novartis and Boehringer Ingelheim issued press releases one after another regarding the acquisition

Novartis acquires Arctos Medical to expand optogenetics product portfolio

This acquisition gives Novartis access to a preclinical optogenetics AAV gene therapy program and Arctos' proprietary technology

Arctos uses adeno-associated virus (AAV) gene therapy technology to deliver and express light genes to specific retinal cells, thereby replacing the function of photoreceptor cells

Arctos mainly develops potential treatments for inherited retinal dystrophy (IRD) and other diseases involving loss of photoreceptors (such as AMD)

Existing gene therapies aim to correct specific genes that cause vision loss

Boehringer Ingelheim acquires Abexxa Biologics to develop new cancer therapies

This acquisition will allow Boehringer Ingelheim to gain the expertise of Abexxa to target cancer-specific proteins located in cells and expand the range of potential cancer antigen targets

Abexxa focuses on the discovery and development of breakthrough antibody drugs, aiming to revolutionize cancer treatment through efficient targeting

Abexxa's innovative platform unlocks the ability to target intracellular antigens of cancer cells by identifying the presentation of MHC1 molecules on the cell surface